In this multicenter , two-stage , double-blind , phase 3 trial , we randomly assigned 753 patients with hyperkalemia to receive either ZS-9 ( at a dose of 1.25 g , 2.5 g , 5 g , or 10 g ) or placebo three times daily for 48 hours .